Tarsier Pharma, an Israel-based Phase 3 biotech developing steroid-free therapies for ocular diseases, filed on Tuesday with the SEC to raise up to $35 million in an initial public offering.
Tarsier Pharma is a late-stage clinical biopharmaceutical firm developing novel therapies for inflammatory eye diseases that can lead to blindness. Its lead platform, based on the immunomodulatory compound dazdotuftide, is designed to treat conditions such as non-infectious anterior uveitis without relying on steroids, which are the current standard of care but can increase the risk of glaucoma. The company is advancing both an eye drop (TRS01) and an injectable formulation (TRS02) to reduce inflammation while avoiding steroid-related side effects, targeting a significant unmet need among patients with uveitis and associated glaucoma.
The Zichron Yaacov, Israel-based company was founded in 2016 and plans to list on the NYSE American under the symbol TARX. Tarsier Pharma filed confidentially on December 29, 2025. Konik Capital Partners is the sole bookrunner on the deal.
